FLT3 and acute myeloid leukemia: Approximately 30% of AML patients harbor some form of FLT3 mutation, which can be divided itself into two mutational classes: internal tandem duplications (FLT3/ITD mutations) in or near the juxtamembrane domain of the receptor and point mutations resulting in single amino acid substitutions involving the activation loop of the tyrosine kinase domain (FLT3/TKD mutations) [94].